Chinese drug makers put on a brave face in the wake of a report that said the Trump administration was considering new restrictions on China-developed medicines, citing the country’s supply chain and cost advantages, according to executives at a forum in Hong Kong on Thursday. While shares of Hong Kong-listed Chinese drug makers plunged after Thursday’s New York Times report that the US government was drafting an executive order to curb licensing deals with China-based firms, pharmaceutical...